INSIGHTS ON EMERGING CAR T THERAPIES

Chimeric antigen receptor (CAR) T-cell treatments have suboptimal performance in the setting of chronic lymphocytic leukemia (CLL), but researchers have identified a potential pathway to increase...

In a multicenter retrospective study published in Blood Advances, authors from multiple institutions examined the impact of prior inotuzumab ozogamicin (InO) exposure on the outcomes of...

Researchers from University Hospital Ostrava and the Faculty of Medicine at the University of Ostrava, Czech Republic, conducted a comprehensive review on how intrinsic T cell characteristics...

Scientists are learning more about how T cell trogocytosis — the exchange of membrane-associated proteins between cells — is regulated, knowledge that could potentially unlock novel...

Developers are encouraged by the robust anti-tumor potency demonstrated by their novel chimeric receptor, the Dual-targeting Synthetic TCR and Antigen Receptor (D-STAR).

Despite ongoing concerns, results from a French database study characterize the risk of secondary cancers after chimeric antigen receptor (CAR) T-cell therapy as very low.